Royal London Asset Management Ltd. Has $8.17 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Royal London Asset Management Ltd. increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 9.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 31,283 shares of the medical instruments supplier’s stock after acquiring an additional 2,572 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Insulet were worth $8,167,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Integrated Wealth Concepts LLC increased its position in shares of Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after acquiring an additional 42 shares in the last quarter. Horizon Investments LLC boosted its stake in Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC boosted its stake in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares during the period. Glenmede Trust Co. NA increased its holdings in Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares in the last quarter. Finally, Graypoint LLC raised its stake in shares of Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on PODD shares. Stifel Nicolaus upped their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada began coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target for the company. TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Wells Fargo & Company increased their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Trading Up 1.1 %

Insulet stock opened at $268.32 on Monday. The stock has a 50-day simple moving average of $272.04 and a 200 day simple moving average of $257.37. The stock has a market capitalization of $18.84 billion, a P/E ratio of 46.34, a PEG ratio of 3.62 and a beta of 1.29. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.47% of the stock is owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.